PolyPeptide Expands Credit Facility to Enhance Financial Structure

PolyPeptide Group AG, a global CDMO specializing in peptide-based pharmaceutical ingredients, has announced the expansion of its existing credit facility to EUR 200 million. This move aims to strengthen the company's financial position. UBS remains the coordinator and agent of the lending syndicate, now including ING Bank alongside Danske Bank and Zürcher Kantonalbank.

This expansion bolsters PolyPeptide’s financial flexibility as it targets doubling its 2023 revenue by 2028. The company anticipates improved profitability and cash flow, driven by ongoing customer funding for significant capacity-expansion projects.

CEO Juan Jose Gonzalez highlights the increased financing capacity as a testament to the confidence of banking partners in PolyPeptide's strategy and growth potential. The company is poised to continue its growth from a solid financial base.